Vivimed Labs Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Santosh Varalwar

Algemeen directeur

₹12.0m

Totale compensatie

Percentage CEO-salaris	100.0%
Dienstverband CEO	33.9yrs
Eigendom CEO	1.6%
Management gemiddelde ambtstermijn	4.6yrs
Gemiddelde ambtstermijn bestuur	22.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Santosh Varalwar's beloning veranderd ten opzichte van Vivimed Labs's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2023	n/a	n/a	-₹3b
Mar 31 2023	₹12m	₹12m	-₹3b
Dec 31 2022	n/a	n/a	-₹809m
Sep 30 2022	n/a	n/a	-₹862m
Jun 30 2022	n/a	n/a	-₹875m
Mar 31 2022	₹12m	₹12m	-₹676m
Dec 31 2021	n/a	n/a	-₹768m
Sep 30 2021	n/a	n/a	-₹1b
Jun 30 2021	n/a	n/a	-₹930m
Mar 31 2021	₹10m	₹10m	-₹719m
Dec 31 2020	n/a	n/a	-₹1b
Sep 30 2020	n/a	n/a	-₹937m
Jun 30 2020	n/a	n/a	-₹1b
Mar 31 2020	₹6m	₹6m	-₹1b
Dec 31 2019	n/a	n/a	-₹485m
Sep 30 2019	n/a	n/a	-₹56m
Jun 30 2019	n/a	n/a	₹391m
Mar 31 2019	₹6m	₹6m	₹574m
Dec 31 2018	n/a	n/a	₹686m
Sep 30 2018	n/a	n/a	₹787m
Jun 30 2018	n/a	n/a	₹825m
Mar 31 2018	₹6m	₹6m	₹779m
Dec 31 2017	n/a	n/a	₹2b
Sep 30 2017	n/a	n/a	₹2b
Jun 30 2017	n/a	n/a	₹2b
Mar 31 2017	₹6m	₹6m	₹2b

Compensatie versus markt: De totale vergoeding ($USD 143.97K ) Santosh } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 42.72K ).

Compensatie versus inkomsten: De vergoeding van Santosh is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Santosh Varalwar (61 yo)

33.9yrs

Tenure

₹12,000,000

Compensatie

Mr. Santosh Varalwar has been the Managing Director of Vivimed Labs Limited since January 27, 2004 and has been its Executive Director since November 09, 1989. Mr. Varalwar served as Chief Executive Office...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Santosh Varalwar	MD & Executive Director	no data	₹12.00m	1.57% ₹ 6.4m
Ramakanta Tripathy	Chief Financial Officer	1.5yrs	₹6.00m	geen gegevens
Yugandhar Kopparthi	Compliance Officer & Company Secretary	no data	₹3.06m	geen gegevens
Manohar Varalwar	Whole Time Director	4.6yrs	₹3.00m	1.25% ₹ 5.1m
Sandeep Varalwar	Executive Director	no data	₹10.00m	2.26% ₹ 9.3m
Mark Robbins	Chief Executive of Uquifa - Vivimed’s API Division	33.8yrs	geen gegevens	geen gegevens

4.6yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van VIVIMEDLAB wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Santosh Varalwar	MD & Executive Director	33.9yrs	₹12.00m	1.57% ₹ 6.4m
Manohar Varalwar	Whole Time Director	28.9yrs	₹3.00m	1.25% ₹ 5.1m
Sandeep Varalwar	Executive Director	15.8yrs	₹10.00m	2.26% ₹ 9.3m
Subhash Varalwar	Non-Executive Promoter Director	33.9yrs	₹175.00k	1.95% ₹ 8.0m
Jamalapuram Hari Gopal	Independent Chairman & Lead Independent Director	3.7yrs	₹375.00k	geen gegevens
Aparna Bidarkar	Non-Executive Independent Woman Director	1.7yrs	₹375.00k	geen gegevens

22.3yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VIVIMEDLAB zijn ervaren en ervaren (gemiddelde ambtstermijn van 22.3 jaar).

Vivimed Labs Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Vivimed Labs Limited, Annual General Meeting, Nov 13, 2023

Vivimed Labs Limited, Annual General Meeting, Mar 27, 2023

Vivimed Labs Limited, Annual General Meeting, Mar 18, 2023

Less than half of directors are independent

Vivimed Labs Limited, Annual General Meeting, Feb 17, 2023

Less than half of directors are independent

Recent updates

Vivimed Labs Limited to Report Q4, 2024 Results on Sep 06, 2024

Vivimed Labs Limited to Report Q4, 2024 Results on May 20, 2024

Vivimed Labs Limited to Report Nine Months, 2024 Results on Feb 14, 2024

Vivimed Labs Limited to Report Q2, 2024 Results on Nov 14, 2023

Vivimed Labs Limited, Annual General Meeting, Nov 13, 2023

Vivimed Labs Limited to Report Q1, 2024 Results on Aug 14, 2023

Full year 2023 earnings released: ₹39.62 loss per share (vs ₹8.16 loss in FY 2022)

Vivimed Labs Limited to Report Q4, 2023 Results on May 30, 2023

Vivimed Labs Limited, Annual General Meeting, Mar 27, 2023

Third quarter 2023 earnings released

Vivimed Labs Limited, Annual General Meeting, Mar 18, 2023

Less than half of directors are independent

Vivimed Labs Limited to Report Q3, 2023 Results on Feb 13, 2023

Vivimed Labs Limited, Annual General Meeting, Feb 17, 2023

Second quarter 2023 earnings released: ₹2.66 loss per share (vs ₹2.81 loss in 2Q 2022)

Less than half of directors are independent

Vivimed Labs Limited to Report Q2, 2023 Results on Nov 14, 2022

First quarter 2023 earnings released: ₹2.68 loss per share (vs ₹0.28 loss in 1Q 2022)

Vivimed Labs Limited to Report Q1, 2023 Results on Aug 12, 2022

Full year 2022 earnings released: ₹8.16 loss per share (vs ₹9.38 loss in FY 2021)

Vivimed Labs Limited to Report Q4, 2022 Results on May 30, 2022

Less than half of directors are independent

Vivimed Labs Limited Appoints Ramakanta Tripathy as Chief Financial Officer

Is Vivimed Labs (NSE:VIVIMEDLAB) Weighed On By Its Debt Load?

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Vivimed Labs Limited Announces Resignation of Umanath Varahabhotla, as an Independent Director

Vivimed Labs Limited to Report Q3, 2022 Results on Feb 14, 2022

Is Vivimed Labs (NSE:VIVIMEDLAB) Using Too Much Debt?

Second quarter 2022 earnings released: ₹2.81 loss per share (vs ₹1.64 loss in 2Q 2021)

Vivimed Labs Limited announced that it expects to receive INR 21.25 million in funding from Yuga Infratech Private Limited, Procon Power Tech Private Limited, Enviro Green Technologies

First quarter 2022 earnings released: ₹0.28 loss per share (vs ₹1.55 profit in 1Q 2021)

Full year 2021 earnings released: ₹9.38 loss per share (vs ₹13.16 loss in FY 2020)

Estimating The Intrinsic Value Of Vivimed Labs Limited (NSE:VIVIMEDLAB)

Vivimed Labs Limited Receives Approval for 2 Products from Uzbekistan Government for Its PICS & Health Canada

Vivimed's FDF Facility in Jeedimetla Obtained Ukraine GMP Approval(Renewal)

Vivimed Labs Limited Receives Approval for Product

Estimating The Intrinsic Value Of Vivimed Labs Limited (NSE:VIVIMEDLAB)

Third quarter 2021 earnings released: ₹5.99 loss per share (vs ₹3.87 loss in 3Q 2020)

New 90-day low: ₹14.65

Vivimed Labs Limited to Report Q3, 2021 Results on Feb 13, 2021

Did Vivimed Labs Limited (NSE:VIVIMEDLAB) Insiders Buy Up More Shares?

Vivimed Labs Limited Announces Re-Designation of Shri. Ramesh Krishnamurthy as Chief Executive Officer-Cum-Chief Financial Officer, Effective December 4, 2020

Vivimed Labs Limited, Annual General Meeting, Dec 30, 2020

Vivimed Labs Limited Announces the Demise of Prof.Bhagvanth Rao Mamidpalli, an Independent Director

Is Vivimed Labs (NSE:VIVIMEDLAB) Using Too Much Debt?

Vivimed Labs Limited Receives Approvals for 3 Ophthalmic Products from Its Sterile Ophthalmic Facility and 3 Oral Liquid Suspension Products from Its Pics & Health Canada

Vivimed Labs Limited to Report Q2, 2021 Results on Nov 14, 2020

Santosh Varalwar acquired an additional 0.5% stake in Vivimed Labs Ltd. (BSE:532660).

Are Insiders Buying Vivimed Labs Limited (NSE:VIVIMEDLAB) Stock?

First quarter earnings released

Vivimed Labs Limited to Report Q1, 2021 Results on Aug 29, 2020

New 90-day high - ₹15.55

Is Vivimed Labs (NSE:VIVIMEDLAB) Using Debt In A Risky Way?

Vivimed Labs Limited to Report Q4, 2020 Results on Jul 25, 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd